An Open-label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Description
Brief Summary
This open-label, multicenter, randomized study compared the efficacy, safety and
pharmacokinetics of obinutuzumab (RO5072759; GA101) 1000 mg versus 2000 mg in participants
with previously untreated CLL. Participants were randomized to receive a maximum of 8 cycles
(28-day cycle) of obinutuzumab (1000 mg intravenous [IV] infusion, on Days 1, 8 and 15 of
Cycle 1 and Day 1 of each subsequent cycle up to 8 cycles or maximum of 8 cycles of
obinutuzumab (2000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of each
subsequent cycle up to 8 cycles.
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
- Confirmed diagnosis of CD20-positive B-cell CLL (per International Workshop on Chronic Lymphocytic Leukemia [IWCLL] guidelines)
- Rai Stage III/IV or Binet Stage C disease, or Rai Stage I/II or Binet Stage B disease that requires treatment according to IWCLL guidelines
- No previous treatment for CLL chemotherapy, radiotherapy or immunotherapy; no previous rituximab treatment for autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP); prior use of steroids for AIHA or ITP is allowed
- Eastern Cooperative Oncology Group performance status of 0, 1 or 2
- Confirmed diagnosis of Transformation of CLL to aggressive B-cell malignancy
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Evidence of severe, uncontrolled concomitant disease
- Known active infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before the start of Cycle 1
- Seropositive for human immunodeficiency virus (HIV)
- Positive for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HBsAg] serology)
- Positive for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
- Pregnant or lactating women
- Concurrent (or within 7 days prior to first dose of study treatment) systemic corticosteroid use, except for low-dose corticosteroid therapy used to treat chronic medical conditions
Sites
-
California
- Unknown facility, Pasadena, California, 91750
- Unknown facility, La Jolla, California, 92093
-
Arizona
- Unknown facility, Tucson, Arizona, 85704
- Unknown facility, Tucson, Arizona, 85715
-
Colorado
- Unknown facility, Colorado Springs, Colorado, 80907
- Unknown facility, Lone Tree, Colorado, 80124
- Unknown facility, Denver, Colorado, 80218
- Unknown facility, Aurora, Colorado, 80012
- Unknown facility, Parker, Colorado, 80138
-
Oregon
- Unknown facility, Portland, Oregon, 97225
-
Washington
- Unknown facility, Vancouver, Washington, 98684
- Unknown facility, Yakima, Washington, 98902
-
Idaho
- Unknown facility, Coeur D'Alene, Idaho, 83814
- Unknown facility, Post Falls, Idaho, 83854
-
Oklahoma
- Unknown facility, Oklahoma City, Oklahoma, 73142
-
Texas
- Unknown facility, Fort Worth, Texas, 76177
- Unknown facility, Dallas, Texas, 75230
- Unknown facility, Dallas, Texas, 75231
-
Kentucky
- Unknown facility, Paducah, Kentucky, 42001
-
Indiana
- Unknown facility, Lafayette, Indiana, 47905
- Unknown facility, Goshen, Indiana, 46526
-
Alabama
- Unknown facility, Birmingham, Alabama, 35249
-
Ohio
- Unknown facility, Kettering, Ohio, 45429